Article Text

Download PDFPDF

  1. Jean-Guillaume Letarouilly1,
  2. Jeremie Sellam2,
  3. Pascal Richette3,
  4. Philippe Dieudé4,
  5. Pascal Claudepierre5,
  6. Corinne Miceli Richard6,
  7. Eric Houvenagel7,
  8. Chi Duc Nguyen8,
  9. Marie-Hélène Guyot9,
  10. Nicolas Segaud10,
  11. Laurent Marguerie11,
  12. Xavier Deprez12,
  13. Jean-Hugues Salmon13,
  14. Guy Baudens14,
  15. Maeva Kyheng15,
  16. Julien Paccou1,
  17. Elisabeth Gervais16,
  18. René-Marc Flipo1
  1. 1Lille University Hospital, Rheumatology, Lille, France
  2. 2Saint-Antoine University Hospital, Rheumatology, Paris, France
  3. 3Lariboisière University Hospital, Rheumatology, Paris, France
  4. 4Bichat University Hospital, Rheumatology, Paris, France
  5. 5Henri Mondor University Hospital, Rheumatology, Créteil, France
  6. 6Cochin University Hospital, Rheumatology, Paris, France
  7. 7Saint-Philibert Hospital, Rheumatology, Lomme, France
  8. 8Béthune Hospital, Rheumatology, Béthune, France
  9. 9Roubaix Hospital, internal medicine, Roubaix, France
  10. 10Armentières Hospital, internal Medicine, armentières, France
  11. 11Calot institute, Rheumatology, Berck-sur-mer, France
  12. 12Valenciennes Hospital, Rheumatology, Valenciennes, France
  13. 13Reims University Hospital, Rheumatology, Reims, France
  14. 14Rheumatology, Private Practice, Valenciennes, France
  15. 15Lille University Hospital, Methodology-Biostatistics and Date Managment Department, Lille, France
  16. 16Poitiers University Hospital, Rheumatology, Poitiers, France


Background Ustekinumab (UST) and secukinumab (SEK) are new Biologic Disease-modifying antiRheumatic Drugs (bDMARDs) available in psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Real-world data are missing for these drugs, despite the wide use. There is only one previous published study including 160 patients (1) receiving UST, but not SEK.

Objectives To evaluate the characteristics of the patients with PsA treated by UST or SEK and to assess real life drug survival and efficacy of UST and SEK in PsA.

Methods This is a national, retrospective, multicentric study from patients suffering from PsA (CASPAR criteria) from July 2011 to april 2018. Drug survival was defined as the time from initiation to discontinuation (stop/switch) of bDMARDs. Kaplan-Meier survival curves and Cox-regression analyses [hazard ratios (HR) and 95% confidence intervals (CIs)] were used adjusting for patient demographics, disease characteristics, co-therapy with methotrexate, and line of treatment with ustekinumab. For peripheral involvement, treatment was considered to be effective for patients with a combined favorable expert opinion and/or > 30% clinical improvement of swollen and tender joint counts. For axial involvement, efficacy criteria were: improvement of BASDAI by at least 2 points on a scale from 0 to 10 or 50% improvement and/or expert opinion.

Results 186 patients were included with a mean follow-up ≥ 6 months: 111 patients under UST and 75 under SEK. The mean age was 51.5 (12.9) years old, 55% of patients were women and the body mass index was 27.3 (5.8) kg/m². The disease duration was 10.8 (8.1) years. Patients were bDMARDs-naïve in 15%. The median drug survivals for UST and SEK were respectively 12 and 14 months (Fig1). A propensity score cannot be used to compare the two bDMARDs, since the number of patients was too small. Smoking was associated with an unfavourable drug survival for SEK (HR= 0.22, 95%CI 0.91), whereas CRP levels were associated with a favorable one for UST (HR=1.009, 95%CI 1.003–1.016). Nine patients under SEK and 2 under UST stopped their treatments due to side effects.

Conclusion This is the first real-world study for drug survival on PsA for SEK and one with the largest number of patients for UST. Drug survival of UST and SEK seems similar to TNF inhibitors’ (2).

References [1] Iannone F, et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic apulian registry (BIOPURE). Clin Rheumatol. 2018;37:667–75.

[2] Walsh JA, et al. Care Spec Pharm. 2018;24:623-631

Abstract aB0760 Figure 1

Drug survival of secukinumab (A) and ustekinumab (B) in psoriatic arthritis

Disclosure of interests Jean-Guillaume Letarouilly: None declared, Jeremie Sellam: None declared, Pascal Richette Consultant for: Grunenthal, Horizon, Speakers bureau: astraZeneca, Grunenthal, Philippe Dieudé: None declared, Pascal Claudepierre Consultant for: Honoraria from Novartis as steering committe of this survey, Corinne Miceli Richard Grant/research support from: MSD, Pfizer, abbVie, Biogen, UCB, Novartis, Consultant for: abbvie, Novartis, BMS, Eric Houvenagel Speakers bureau: Lilly, Novartis, Janssen, Chi Duc Nguyen: None declared, Marie-Hélène Guyot: None declared, Nicolas Segaud: None declared, Laurent Marguerie: None declared, Xavier Deprez Speakers bureau: Novartis Janssen, Jean-Hugues Salmon Speakers bureau: Janssen Novartis, Guy Baudens Grant/research support from: Financial Grant from NordicPharma, Consultant for: Roche SAS, Maeva Kyheng: None declared, Julien Paccou Speakers bureau: Novartis Janssen, Elisabeth Gervais Grant/research support from: Roche, Pfizer, Consultant for: Bristol-Myers Squibb, UCB, René-Marc Flipo Consultant for: Honoraria from Novartis as steering committe of this survey

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.